| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 25066 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab as a monotherapy for the treatment of resectable, locally-advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS ≥ 1. |
| Assessment Process | |
| Rapid review commissioned | 10/11/2025 |
| Rapid review completed | 09/12/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication as an adjunct to the current standard of care. |
| Full HTA commissioned by the HSE | 19/12/2025 |
| Pre-submission consultation with Applicant | 03/02/2026 |
| Full submission received from Applicant | 09/06/2026 |
| Preliminary review sent to Applicant | 16/07/2026 |
| NCPE assessment re-commenced | 14/08/2026 |
| Factual accuracy sent to Applicant | 09/10/2026 |
| NCPE assessment re-commenced | 15/10/2026 |
| NCPE assessment completed | 30/10/2026 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab, for the indication under assessment, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*Next steps: The NCPE Assessment Report and recommendation and Patient Organisation submission, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health Pricing and Supply of Medical Goods Act 2013.
Further information on this process may be found here.
Please see the HSE Pricing and Reimbursement Tracker for any updates on the reimbursement status of this drug.
